Biote Schedules Fourth Quarter and Full Year 2025 Financial Results Release and Conference Call
MWN-AI** Summary
Biote Corp. (Nasdaq: BTMD), a leader in hormone replacement therapy and healthy aging solutions, has announced the schedule for its financial results for the fourth quarter and full year of 2025. The results will be disclosed on Wednesday, March 11, 2026, following the market's closure. A conference call to discuss the findings will take place that same day at 5:00 PM ET. Interested participants can join the call by dialing (844) 481-2820 for U.S. callers or (412) 317-0679 for international attendees. Additionally, a live webcast will be available through the Biote Investor Relations website, allowing wider access to the discussion. A recorded version of the webcast will be accessible shortly after the event for those unable to attend live.
Biote aims to enhance the healthspan of patients through innovative hormone optimization solutions. With its extensive network of certified providers, the company collaborates with leading clinicians to help restore vitality and promote healthier aging. The firm has indicated that its forthcoming financial disclosures will also include forward-looking statements about its performance and strategic initiatives. These statements will encompass various potential risks and uncertainties, ranging from market acceptance and regulatory conditions to competition and geopolitical factors.
Investors and stakeholders are encouraged to review these upcoming results, as well as consider the potential implications of the forward-looking statements within the context of Biote's ongoing business strategy. Notably, these statements reflect current expectations, and readers should be aware of the possibility of significant deviations from anticipated outcomes due to various external factors. For further inquiries, the Investor Relations contact is Eric Prouty at AdvisIRy Partners, while media inquires can be directed to the company via email.
MWN-AI** Analysis
Biote Corp. (Nasdaq: BTMD) is set to release its fourth quarter and full-year financial results for 2025 on March 11, 2026, which presents several key considerations for investors. As a leading provider of hormone replacement therapy and healthy aging solutions, Biote's financial performance can significantly influence its stock price and market perception.
Investors should closely monitor the conference call scheduled for that day at 5:00 p.m. ET, where management will discuss the results and provide insights into future strategies. This is a critical opportunity to assess the company’s performance relative to market expectations, particularly given the forward-looking statements highlighted in their previous communications. The upcoming results may reveal crucial data on revenue growth, profitability margins, and the performance of their hormone optimization solutions, which are vital to understanding Biote's competitive standing in the healthcare market.
Potential challenges were also mentioned in their previous correspondence, including reliance on third-party manufacturing and adherence to stringent regulatory conditions. Investors should be cautious of these risks, especially as competitive pressures increase in the rapidly evolving health and wellness sector.
Given the current economic climate and potential fluctuations in customer demand for wellness products, Biote's ability to navigate these hurdles will be key to its future growth. As comparisons to previous quarters take shape, analysts’ expectations around the efficacy of organizational restructuring and market adaptation will be pivotal.
In conclusion, while Biote presents a promising growth opportunity, potential investors should exercise due diligence. Watching for signs of consistent revenue growth and strategic market positioning during the earnings call will be essential in forming a well-rounded view of the company's health and market trajectory. As with any investment, weigh the risks against the potential rewards carefully.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator advancing the healthspan of patients’ lives by providing hormone replacement therapy and healthy aging solutions, today announced the Company will provide fourth quarter and full year financial results on Wednesday, March 11, 2026, after the close of the market. A conference call to discuss the firm’s results will be held at 5:00 p.m. ET. the same day.
Conference Call Details
The conference call may be accessed by dialing (844) 481-2820 (U.S. toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Fourth Quarter Earnings Call . A replay of the webcast will be available on the Events page of the Biote Investor Relations website, found here , shortly after the event concludes.
About Biote
Biote advances the healthspan of our Practitioners’ patients by providing innovative hormone optimization and healthy aging solutions. Through our network of Biote-certified providers, we collaborate with leading clinicians to restore vitality and promote vibrant aging.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words “may,” “can,” “should,” “will,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “hope,” “believe,” “seek,” “target,” “continue,” “could,” “might,” “ongoing,” “potential,” “predict,” “would” and other similar expressions, are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: anticipated benefits and successful execution of our organizational restructuring; the success of our dietary supplements to attain significant market acceptance among clinics, practitioners and their patients; our customers’ reliance on certain third parties to support the manufacturing of bio-identical hormones for prescribers; our and our customers’ sensitivity to regulatory, economic, environmental and competitive conditions in certain geographic regions; our ability to increase the use by practitioners and clinics of the Biote Method at the rate that we anticipate or at all; our ability to grow our business; the significant competition we face in our industry; the impact of strategic acquisitions and the implementation of our growth strategies; our ability to protect our intellectual property; the heavy regulatory oversight in our industry; changes in applicable laws or regulations; changes to international tariffs, U.S. trade policy or similar government actions; geopolitical tensions; the inability to profitably expand in existing markets and into new markets; the possibility that we may be adversely impacted by other economic, business and/or competitive factors, including the impact of hurricanes and other natural disasters; and future exchange and interest rates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and other risks and uncertainties described in the “Risk Factors” section of Biote’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission (the “SEC”) on March 14, 2025, Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025, filed with the SEC on November 7, 2025, and other documents filed by Biote from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Biote assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Biote does not give any assurance that it will achieve its expectations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260225925206/en/
Investor Relations:
Eric Prouty
AdvisIRy Partners
eric.prouty@advisiry.com
Media:
Press@biote.com
FAQ**
What specific financial metrics should investors pay attention to during the upcoming Biote Corp. BTMD conference call on March 12026, that may indicate the company's growth potential?
How does Biote Corp. BTMD plan to address the competition in the hormone replacement therapy market and what strategies are in place to increase market share?
Given the various forward-looking statements made, what are Biote Corp. BTMD’s primary strategies to mitigate risks associated with regulatory changes and market acceptance of its products?
Can you elaborate on how Biote Corp. BTMD intends to leverage strategic acquisitions to enhance its growth strategy and operational capabilities following the upcoming earnings report?
**MWN-AI FAQ is based on asking OpenAI questions about Biote Corp. (NASDAQ: BTMD).
NASDAQ: BTMD
BTMD Trading
-8.12% G/L:
$1.755 Last:
94,348 Volume:
$1.90 Open:
